Novo's €2.6bn Ablynx Bid Opens The Door For Better Offers

 
• By Lucie Ellis-Taitt

Gilead, Amgen and AbbVie are names that could join the fray should a bidding war start for Nanobody drug developer Ablynx, which has rebuffed two takeover offers from Novo Nordisk.

Auction
Could rival bidders bring in better offers to acquire Ablynx? • Source: Shutterstock

More from Deals

More from Business